Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Alparslan MerdinMerih Kızıl ÇakarMehmet Sinan DalDuygu MertJale YıldızSemih BaşçıMehmet BakırtaşTahir DarçınDerya ŞahinBahar Uncu UluTuğçe Nur YiğenoğluHikmettullah BatgiAyşegül TetikDicle İskenderFevzi AltuntaşPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Administering ABVD chemotherapy to patients with moderate neutropenia seems to be safe.